University Health Network

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. A registrational cohort is ongoing to further evaluate poze-cemdi against eculizumab.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with 96% achieving LDH control vs. 80% on ravulizumab. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration with infrequent dosing.

Phase 3 trial data shows poze-cemdi, a first-in-class combination treatment, outperforms standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. Ongoing studies aim to confirm these findings.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with better LDH levels. A registrational cohort is ongoing, comparing poze-cemdi to eculizumab. Poze-cemdi offers potential for self-administration and improved disease control.

Phase 3 trial data showed the poze-cemdi combination treatment achieved better disease control in PNH patients, measured by LDH levels, compared to standard ravulizumab. Poze-cemdi, combining an antibody and siRNA targeting C5, demonstrated superior LDH control and normalization, with potential for self-administration, indicating a promising treatment approach for PNH and other complement-mediated diseases.

Phase 3 trial data showed poze-cemdi combo treatment improved LDH control in PNH patients compared to ravulizumab, with 96% achieving adequate LDH control and 93% achieving normalization. A registrational cohort is ongoing, comparing poze-cemdi against eculizumab.

Pozelimab and cemdisiran combination shows superior inhibition of terminal complement in PNH patients, achieving higher LDH control and normalization rates compared to ravulizumab, with potential for self-administration.

UHN in Toronto selected as first Canadian site for Neuralink's BCI clinical trial (CAN-PRIME) for ALS and spinal cord injury patients. The trial aims to enroll up to six adult patients, followed for up to six years, evaluating the safety and functionality of the N1 implant and R1 robot. The N1 implant, surgically placed in the brain, enables quadriplegics to control external devices with thoughts. Similar trials, PRIME and CONVOY, are ongoing in the U.S.

Galleri, a blood test screening for multiple cancers, is now available in Canada through Wellness Haus for $2,099. Despite initial enthusiasm, concerns about its effectiveness and potential for false positives temper its adoption. The test, not yet proven to improve patient outcomes, detects cancer DNA in 1-1.5% of people, but does not specify cancer type. Ongoing trials aim to determine its feasibility as a screening tool.

Neuralink receives Health Canada approval for CAN-PRIME trial to assess safety and functionality of its implantable brain-computer interface (BCI) device, targeting individuals with ALS or cervical spinal cord injury at UHN's Toronto Western Hospital.